Prorenin processing by cathepsin B in vitro and in transfected cells  by Jutras, Isabelle & Reudelhuber, Timothy L.
Prorenin processing by cathepsin B in vitro and in transfected cells
Isabelle Jutras, Timothy L. Reudelhuber*
Laboratory of Molecular Biochemistry of Hypertension, Clinical Research Institute of Montreal, 110 Pine Avenue West,
Montreal, Que. H2W 1R7, Canada
Received 14 December 1998
Abstract Renin, which catalyzes the initial proteolytic cleavage
reaction in the production of angiotensins, is first synthesized as
a zymogen, prorenin, and requires the proteolytic removal of an
amino-terminal prosegment for activation in vivo. The lysosomal
hydrolase cathepsin B has been proposed as a prorenin processing
enzyme based on reports of its co-localization with renin in the
secretory granules of certain tissues and its ability to activate
prorenin in vitro. In the current study, scanning mutagenesis was
used to identify the amino acids which determine the site
selectivity of prorenin cleavage by human cathepsin B in vitro.
Co-expression assays in AtT-20 cells were also used to test for
the ability of cathepsin B to cleave human prorenin within cells.
Our results suggest that a basic lysine residue at the 32 position
from the cleavage site is required for cathepsin B cleavage of
prorenin in vitro and that the structure of prorenin itself may
account for the selection of the proper cleavage site. In addition,
although cathepsin B appears to be correctly sorted to lysosomes,
the enzyme exhibits prorenin processing activity in transfected
AtT-20 cells, raising the question of the cellular localization in
which the processing event occurs.
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1. Introduction
The aspartyl protease renin catalyzes the rate-limiting step
in the generation of angiotensins by cleaving circulating an-
giotensinogen in the renin angiotensin system (RAS).
Although the main source of plasma active renin is the kidney
[1], many other tissues express the renin gene [2^5]. Some of
these tissues have been shown to express the other compo-
nents of the RAS suggesting the existence of locally active
tissue RASs. Like many proteases, renin is ¢rst synthesized
as a larger inactive precursor, prorenin. In humans, processing
of prorenin to active renin involves the proteolytic cleavage of
a 43 amino acid prosegment following a pair of basic amino
acids (Lys-Arg) and occurs speci¢cally in secretory granules
[6]. Indeed, cultured cells devoid of these organelles are unable
to process prorenin in transfection assays [7]. In vivo, it is
possible that multiple prorenin processing enzymes (PPE) ex-
ist and are active in di¡erent renin-producing tissues [8,9].
Cathepsin B was ¢rst proposed as a renal PPE on the basis
of its ability to cleave prorenin in vitro [10] and more recently,
on its capability to process prorenin co-transfected with ca-
thepsin B in GH4C1 cells [11]. Immunohistochemistry studies
have also indicated that renin and cathepsin B are co-localized
in granules of di¡erent tissues: epithelial cells of the renal
proximal tubule [12], human pituitary lactotrophs [13], mouse
adrenocortical cells [14] and submandibular gland [15], rat
anterior pituitary gonadotrophs [16] and juxtaglomerular cells
[17]. Cathepsin B is most commonly known as a lysosomal
cysteine protease of the papain superfamily that possesses
endopeptidase as well as exopeptidase activities with complex
pH dependencies [18]. Its endopeptidase activity was reported
to show broad speci¢city with a preference for basic (partic-
ularly Arg) and aromatic (particularly Phe) residues at the 32
position from the cleavage site [19]. However, these data have
mostly been established using synthetic peptide substrates and
little evidence exists regarding the amino acids important for
the selection of the proper cleavage site by cathepsin B with
protein substrates like prorenin.
Cathepsin B is synthesized as a glycosylated zymogen of 39
kDa that is converted to a 33 kDa active form by the proteo-
lytic removal of the prosegment. The activation of procathep-
sin B has been proposed to result from an intramolecular
autocatalytic event that occurs primarily within the lysosome
in the pH range of 4^6 [20]. Additional processing of active
cathepsin B involves an internal cleavage that generates
the active two-chain form containing a heavy chain of
27 kDa and a light chain of 5 kDa, linked by a disul¢de
bridge [21]. In order to act as a PPE, cathepsin B would
need to be capable of su⁄cient autoactivation within the se-
cretory pathway to be active on the prorenin in the secretory
granules.
In the current study we have sought to identify the protein
sequences which dictate the cleavage speci¢city of human
cathepsin B on prorenin and to test whether cathepsin B is
capable of cleaving human prorenin when co-expressed in
cells containing secretory granules.
2. Materials and methods
2.1. Recombinant plasmid construction
Construction of the expression vectors for native human prorenin
and for prorenins generated by site-directed mutagenesis around the
Lys-Arg cleavage site have been described previously [22]. The expres-
sion vector for human procathepsin B was generated by overlap ex-
tension polymerase chain reaction (PCR) [23] of the human cathepsin
B cDNA ([24]; a gift from Dr. D. Steiner) using the following oligo-
nucleotides: forward: 5P-CGCGATATCGAGTAGTGGATCTAGG-
3P ; reverse: 5P-GCGGGATCCCAGGACTGGCACGAC-3P. The am-
pli¢ed fragment was digested with the restriction enzymes EcoRV and
BamHI (recognition sites underlined in the amplifying oligonucleoti-
des) and was inserted into the RSV globin expression vector [25]. The
entire coding sequence of cathepsin B was veri¢ed by DNA sequenc-
ing.
2.2. Cell culture
GH4C1 and AtT-20 cells were cultured in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 5% fetal bovine serum
(FBS), 0.1% SerXtend (Irvine Scienti¢c, Santa Ana, CA) and 10 Wg/ml
gentamicin.
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2.3. Assay of prorenin processing by cathepsin B in vitro
GH4C1 cells were plated at a concentration of 106 cells per 35 mm
well and transfected 24 h later with 20 Wg of an expression vector for
native prorenin or a mutated prorenin using the lipofectin reagent
method (Gibco-BRL). After 48 h of incubation, the transfected cells
were transferred to 25 mm wells; 24 h later the transfected cells were
incubated 2 h with methionine-free DMEM and labeled overnight
with 300 WCi of [35S]methionine per well in serum-free medium. Cul-
ture supernatants containing labeled native prorenin or mutated pro-
renins constitutively secreted by the transfected cells, were collected
and their pH was lowered by the addition of MES bu¡er (pH 6.0) to a
¢nal concentration of 100 mM MES with 1 mM EDTA, 5 mM di-
thiothreitol and 0.001% BSA. Bu¡ered supernatants were incubated
with or without 0.4 units of cathepsin B puri¢ed from human liver
(Calbiochem) at 37‡C for up to 6 h. The supernatants were subse-
quently immunoprecipitated with an anti-human renin antibody and
analyzed by SDS-PAGE followed by £uorography as previously de-
scribed [25]. The relative intensities of the bands corresponding to
prorenin and renin were evaluated by scanning densitometry of auto-
radiograms using an IS-1000 Digital Imaging System (Alpha Innotech
Corporation).
2.4. Transient expression in AtT-20 cells
Puri¢ed expression vectors for native or mutated prorenin and for
cathepsin B or a control plasmid (50 Wg total DNA) were mixed with
107 AtT-20 cells and electroporated with a single pulse of 300 V/4
mm, 1000 WF. Electroporated cells were then transferred to 25 cm2
£asks; the next day, the cells were transferred to 12 well plates at a
concentration of 5U105 cells per well. Twenty-four hours later, cells
were incubated for 2 h with methionine-free DMEM containing 10%
dialysed FBS, followed by a 5 h labeling period using 300 WCi of
[35S]methionine per well. Tunicamycin treated cells were incubated
3 h with methionine-free DMEM with or without tunicamycin at a
dose of 15 Wg/ml, labeled for 2 h and chased overnight in complete
DMEM with or without tunicamycin.
2.5. Detection of renin and prorenin
Supernatants from labeled AtT-20 cells were immunoprecipitated
using an anti-human renin antibody as described above; in parallel,
secreted prorenin and renin were dosed using an angiotensin I gener-
ation assay followed by an angiotensin I radioimmunoassay described
previously [22]. Brie£y, supernatants were incubated with an excess
angiotensinogen either directly (active renin content), or following an
incubation with trypsin (total renin content=prorenin+renin). The
percentage of active renin was calculated as (active renin content/total
renin content)U100.
2.6. Immunoprecipitation of human cathepsin B
Culture supernatants from labeled AtT-20 cells were collected and
the cells were lysed in 10 mM Tris pH 8, 150 mM NaCl, 1 mM
EDTA, 0.1% SDS, 2% NP-40. Cell lysates and supernatants were
immunoprecipitated with an anti-human cathepsin B antibody and
analyzed by SDS-PAGE followed by £uorography as previously de-
scribed [25].
3. Results
Determinants of cathepsin B cleavage of prorenin were
evaluated using mutated prorenins, shown in Fig. 1, generated
by alanine scanning mutagenesis in the region of the reported
cleavage site [26]. The vectors expressing the native or mu-
tated prorenins were transfected in GH4C1 cells. These cells
lack the capacity to process prorenin and constitutively secrete
the unprocessed protein in the medium [7,27]. Following
transfection, the cells were labeled overnight using
[35S]methionine. The next day, supernatants were collected
and then incubated with puri¢ed human liver cathepsin B
for up to 6 h at 37‡C in a pH 6 bu¡er [26]. The generation
of active renin was quantitated by scanning densitometry of
autoradiograms. Digestion of native (non-mutated) human
prorenin with cathepsin B under these conditions leads to a
slow generation of active renin as con¢rmed by electropho-
retic migration (Fig. 2) and renin activity assay (data not
shown). In the time course of the digestion, no other degra-
dation products appeared and no cleavage occurred in the
absence of added cathepsin B (Fig. 2, 3Cathepsin B). These
results con¢rm that under the conditions used, human ca-
thepsin B displays a high degree of cleavage site selectivity
on human prorenin [10].
Fig. 3 shows the time course of cathepsin B cleavage of
prorenins mutated at single amino acids in the region of the
reported cleavage site. As with native prorenin, cathepsin B
processed all of the mutated prorenins slowly and without
showing any signs of non-speci¢c degradation (data not
shown). The overall e¡ect of mutating residues to alanine
on the amino-terminal side of the reported cleavage site was
to diminish the processing e⁄ciency by cathepsin B (Fig. 3, N-
term.; dashed lines). Mutations on the carboxy-terminal side
of the cleavage site (Fig. 3, C-term.; dashed lines) resulted in
cleavage e⁄ciencies that were equal to or greater than those
obtained with native prorenin. The most marked e¡ect on
cleavage e⁄ciency was observed with the mutation of the
lysine at position 32 (K/A32; numbering relative to the re-
ported cathepsin B cleavage site) which virtually abolished
cleavage by cathepsin B. The dependence of prorenin cleavage
on the presence of the lysine residue was also observed using
crystallographic grade recombinant human cathepsin B puri-
¢ed from yeast (a gift from Dr. John S. Mort) that e⁄ciently
processed native prorenin but showed no activity towards the
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Fig. 1. Schematic representation of the alanine scanning mutations
of residues around the cleavage site in human prorenin. Amino
acids are represented by their one-letter code. Arrow indicates na-
tive processing site in human prorenin. Numbering is relative to
amino acid 1 of active renin.
Fig. 2. In vitro cleavage of human prorenin by human cathepsin B.
Tissue culture supernatant containing native (non-mutated) recombi-
nant human prorenin was incubated with puri¢ed human cathepsin
B for the indicated times and was immunoprecipitated with anti-re-
nin/prorenin antibody. The expected migration for prorenin and re-
nin was determined by co-electrophoresis of size markers.
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K/A32 mutant (data not shown), con¢rming that the cleav-
age of prorenin was not due to a contamination of the com-
mercial preparation of cathepsin B.
To test if the processing activity observed in vitro could
also take place in cultured cells, AtT-20 cells were used for
co-transfection assays of prorenin and cathepsin B, since these
cells represent an appropriate model to study prorenin proc-
essing [28]. AtT-20 cells contain an endogenous protease ca-
pable of activating native human prorenin ([28] and Fig. 4A),
but this enzyme is incapable of cleaving prorenin mutated at
the 31 position from the cleavage site ([22] and Fig. 4A).
Since this mutated prorenin is processed by cathepsin B in
vitro (Fig. 3, R/A31), AtT-20 cells were co-transfected with
the expression vectors for the mutated R/A31 prorenin and
human cathepsin B. Whereas expression of the R/A31 mu-
tant prorenin alone leads to the secretion of the unprocessed
form only (Fig. 4A), co-transfection of cathepsin B and R/
A31 prorenin results in the secretion of the lower molecular
weight form corresponding to active renin (Fig. 4A). It is
noteworthy that the endogenous cathepsin B in AtT-20 cells,
which is of murine origin, is incapable of processing the R/
A31 mutant prorenin, possibly indicating that murine and
human cathepsins B have a di¡erent substrate speci¢city.
The activity of the secreted R/A31 renin was assessed using
an angiotensin I generation assay which indicated that AtT-20
cells secreted 33% active renin when co-transfected with the R/
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Fig. 3. Time course of activation of mutated prorenins by cathepsin
B. Culture supernatants containing recombinant human mutated
prorenins were subjected to limited digestion by human cathepsin B
as shown in Fig. 1. Scanning densitometry was used to determine
the percentage conversion to active renin. Solid lines and dashed
lines represent the average time course of activation of native and
the corresponding mutated prorenins, respectively. Nomenclature
represents the mutation induced (e.g., K/A means a Lys is replaced
with an Ala) and the position of the mutation with reference to the
reported cleavage site for cathepsin B [26]. *P6 0.05; **P6 0.01 as
compared to native prorenin using Dunn’s multiple comparisons
test. Data are derived from 3^4 independent assays.
Fig. 4. A: Processing of human prorenin by human cathepsin B in
AtT-20 cells. AtT-20 cells were electroporated with expression vec-
tors for the indicated proteins. Following labeling of the cells,
supernatants were immunoprecipitated with anti-renin/prorenin anti-
body. Protein bands corresponding to prorenin and renin are
marked by arrows. Representative data are shown from one of six
such experiments. B: Secretion of active renin by AtT-20 cells co-
transfected with human prorenin and human cathepsin B. Prorenin
and renin secreted in the supernatants of AtT-20 cells electroporated
with expression vectors for the indicated proteins were dosed using
an angiotensin I generation assay. **P6 0.01 as compared to R/
A31 Proren+Control using Student’s t-test.
I. Jutras, T.L. Reudelhuber/FEBS Letters 443 (1999) 48^5250
A31 mutant prorenin and cathepsin B (Fig. 4B). Thus ca-
thepsin B exhibits prorenin processing activity both in vitro
and in transfected AtT-20 cells.
Since procathepsin B is normally sorted to lysosomes while
prorenin enters the regulated secretory pathway, the capacity
of cathepsin B to process prorenin raises the question of the
organelle localization in which the processing event occurs. As
shown in Fig. 5A, AtT-20 cells transfected with human ca-
thepsin B expressed abundant amounts of the enzyme in the
active form as demonstrated by the presence of the 33 kDa
single chain form and the 27 kDa subunit of the active en-
zyme. Labeled cathepsin B also appeared to be retained in the
cell since no signi¢cant accumulation of the enzyme could be
observed in the supernatant even after a 5 h secretion period
(Fig. 5A). As lysosomal targeting of cathepsin B is mediated
by modi¢ed mannose residues in the glycoprotein, cells were
treated with tunicamycin, an inhibitor of glycosylation, to
con¢rm that such a treatment would prevent human cathepsin
B export to the lysosomes and therefore determine if the ex-
pressed protein was correctly sorted. The results demonstrate
that tunicamycin treatment leads to a dramatic decrease of the
active forms of human cathepsin B within the cell and the
appearance of a higher molecular weight form in both the
cells and the supernatant (Fig. 5B). This slower migrating
form possibly corresponds to unglycosylated procathepsin B
expected to be around 35 kDa. The levels of cathepsin B that
could be immunoprecipitated both intracellular and extracel-
lular were also markedly decreased and could re£ect degrada-
tion of cathepsin B retained in the secretory pathway. In ad-
dition, when AtT-20 cells co-expressing the R/A31 prorenin
and human cathepsin B were treated with tunicamycin, only
prorenin was found to be secreted in the medium (data not
shown). Thus, human cathepsin B expressed in AtT-20 under-
goes intracellular sorting in a glycosylation-dependent manner
consistent with its sorting to the lysosomal compartment.
4. Discussion
Our current results support the previously reported role of
cathepsin B in site-selective cleavage of human prorenin in
vitro [26] and demonstrate that this cleavage is critically de-
pendent on the lysine at position 42 in the prorenin proseg-
ment. Based on the proposed mechanism of cathepsin B ac-
tion on synthetic substrates [19], the resulting scissile bond
would follow Arg-43, consistent with the reported amino-ter-
minus of the renin produced after cathepsin B digestion of
human prorenin [26]. Cathepsin B cleavage of substrates con-
taining Arg at the 32 position (relative to the cleavage site)
depends on a group with pKa of 5.1 (suggested to be Glu-245)
that has been proposed to interact with the Arg side chain and
stabilize the transition state [19]. Similarly, crystal structure
modeling predicts Glu-245 could also achieve e⁄cient electro-
static interaction with Lys at the 32 position from the cleav-
age site [29]. Although human prorenin contains several other
basic residues which could serve as potential cathepsin B
cleavage sites [30] its preferential cleavage at position 43 in
the prosegment re£ects that of numerous other proteases in-
cluding trypsin, thermolysin, kallikrein, plasmin and pepsin
[31,32]. This site selectivity is thus quite likely to be a result
of a combination both of site preference by cathepsin B and
of the masking of additional cleavage sites due to the confor-
mation of prorenin.
Comparison of the known protein sequences for prorenin
indicates that the critical lysine in human prorenin cleavage by
cathepsin B is conserved between species in the homologous
proteins. In addition, this lysine is found at the 32 position
from the cleavage site of mouse submaxillary prorenin [33,34].
However, N-terminal sequencing of rat renal renin has indi-
cated cleavage at a site further C-terminal relative to the con-
served lysine [35,36]. Thus it is still uncertain if the identity of
the renal PPE is conserved between species.
Procathepsin B activation has been shown to occur prefer-
entially in an acidic pH range of 4^6 and may be the result of
an intramolecular autoactivation mechanism [20]. Denatura-
tion of active cathepsin B increases exponentially with increas-
ing pH and the enzyme is irreversibly inactivated at pH 7.0
[37]. Tumor-derived endocrine cell lines and particularly AtT-
20 cells are known to exhibit a high rate of basal unstimulated
release of granule content [38]. However, when AtT-20 cells
were transfected with human cathepsin B, the mature enzyme
could not be detected in the supernatant making it unlikely
that the expressed protein was routed to the secretory path-
way to be co-secreted with renin. Furthermore, retention of
cathepsin B in the cells was dramatically decreased when gly-
cosylation of the protein was inhibited indicating normal traf-
¢cking of cathepsin B to the lysosomes. These results raise the
question of how cathepsin B could cleave prorenin if the two
proteins are not co-resident within the cells.
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Fig. 5. A: Expression of human cathepsin B in transfected AtT-20
cells. AtT-20 cells were electroporated with an expression vector for
human cathepsin B (+) or a control plasmid (3). Following pulse
labeling of the cells for 5 h, cathepsin B was immunoprecipitated
from supernatants (Media) and cell lysates (Cells) using an antibody
speci¢c for human cathepsin B. B: Sorting of human cathepsin B in
AtT-20 cells. AtT-20 cells transfected with cathepsin B were pulse-
labeled for 2 h and chased overnight, in the absence (3) or presence
(+) of tumicamycin. Cathepsin B was immunoprecipitated as de-
scribed above. Active forms of cathepsin B are indicated by arrows
and the precursor form by a dashed arrow. Numbers at the left of
the autoradiogram represent the apparent molecular weights (in
kDa) of co-electrophoresed size markers. The data shown are from
a representative experiment (of three).
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In pancreatic L-cells, proinsulin and procathepsin B have
been shown to be transiently associated in the immature se-
cretory granules and to segregate to their respective cellular
destinations as the secretory granule matures [39]. As the en-
vironment progressively acidi¢es in the trans-Golgi and in
budding immature granules [40], it is possible that some de-
gree of cathepsin B activation occurs before it is sorted to the
lysosomes. In the context of an overexpression system such as
transfected AtT-20 cells, this might generate su⁄cient active
cathepsin B to process prorenin. It is unclear, however, if such
a process is responsible for prorenin processing in renin-pro-
ducing tissues. The granules of renal juxtaglomerular cells
have been reported to contain numerous lysosomal enzymes
and autophagic particles [17]. Prolonged storage of prorenin
in these granules in the presence of an active form of cathep-
sin B could overcome the limitation of the apparently slow
kinetics of cathepsin B action on prorenin seen in vitro [26].
Immunohistochemical studies have shown renin and ca-
thepsin B co-staining in subcellular compartments of numerous
tissues. In some cases, this possibly represents cathepsin B co-
localization with renin in late endosomes or lysosomes which
have taken up prorenin from the extracellular space. For ex-
ample, the cortical proximal tubules of the kidney contain
signi¢cant amounts of immunoreactive renin [12], although
they appear to synthesize very little renin mRNA [41]. Immu-
noelectron microscopy of proximal tubular cells suggests that
this renin is in lysosomes, consistent with its absorption from
the lumen of the collecting duct [12]. Indeed, studies of mon-
keys injected with puri¢ed labeled human prorenin demon-
strate that both the kidney and liver are involved in clearing
the protein from the circulation and that the initial step in its
degradation in the lysosomes involves an apparent removal of
the prosegment [42]. While such a process would not be likely
to play a major role in the generation of active renin for
secretion, its importance in the generation of angiotensins
within tissues or cells [43] remains an interesting topic for
further study.
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